Literature DB >> 10965246

Effect of beta-blocker eyedrops on corneal epithelial barrier function.

A Niiya1, N Yokoi, Y Matsumoto, A Komuro, T Ishibashi, S Tomii, J He, S Kinoshita.   

Abstract

To investigate the long-term effect of a topically applied beta-blocker on human corneal epithelium, the corneal epithelial barrier function and the superficial cell area of the corneal epithelium were evaluated. Seventeen normal healthy volunteers (without medication), 7 cataract patients (treated with pyrenoxine eyedrops) and 7 glaucoma or ocular hypertension patients (treated with 0.5% timolol maleate) were assigned to this study. The eyedrops had been used on a daily basis for at least 3 months. In the evaluation of corneal epithelial barrier function, fluorescein uptake was measured using a slitlamp fluorophotometer after application of 3 microl of 0.5% fluorescein for 10 min. In the evaluation of the superficial cell area, the central corneal epithelium was measured by tandem scanning confocal microscopy (TSCM). The healthy control and timolol groups were compared. Corneal fluorescein uptake in the healthy control, pyrenoxine and timolol groups was 20.3 +/- 3.2, 21.5 +/- 4.0 and 76.2 +/- 30.0 ng/ml (mean +/- standard error), respectively. There was a significantly higher fluorescein uptake in the timolol group compared to the pyrenoxine group (p = 0.0088) and the healthy control group (p = 0.0055). TSCM showed no significant difference in the superficial cell areas of the corneal epithelium between the healthy control and timolol groups. beta-Blocker eyedrops decreased the corneal epithelial barrier function. Their application was not accompanied by any biomicroscopic change in the superficial cell area. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965246     DOI: 10.1159/000027515

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  9 in total

1.  [Glaucoma and corneal transplantation].

Authors:  G Geerling; M Müller; M Zierhut; T Klink
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

Review 2.  In vivo confocal microscopy of the human cornea.

Authors:  I Jalbert; F Stapleton; E Papas; D F Sweeney; M Coroneo
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

Review 3.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

4.  Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells.

Authors:  Kazuhide Kawase; Wenzhong Lin; Yumiko Aoyama; Tetsuya Yamamoto; Masamitsu Shimazawa; Hideaki Hara
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

Review 5.  Graft failure: III. Glaucoma escalation after penetrating keratoplasty.

Authors:  Emily C Greenlee; Young H Kwon
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

6.  The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients.

Authors:  Naoto Tokuda; Yasushi Kitaoka; Akiko Matsuzawa; Junsuke Miyamoto; Shinsuke Sakae; Yasunari Munemasa; Hitoshi Takagi
Journal:  J Ophthalmol       Date:  2015-05-10       Impact factor: 1.909

Review 7.  Challenges in the complex management of post-keratoplasty glaucoma.

Authors:  Lisa-Marie Anders; Zisis Gatzioufas; Matthias C Grieshaber
Journal:  Ther Adv Ophthalmol       Date:  2021-07-20

8.  β-blocker eye drops affect ocular surface through β2 adrenoceptor of corneal limbal stem cells.

Authors:  Xingyue Yuan; Xiubin Ma; Lingling Yang; Qingjun Zhou; Ya Li
Journal:  BMC Ophthalmol       Date:  2021-12-05       Impact factor: 2.209

Review 9.  The Possible Positive Mechanisms of Pirenoxine in Cataract Formation.

Authors:  Phit Upaphong; Chanisa Thonusin; Janejit Choovuthayakorn; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.